Ocuphire Granted Two New U.S. Patents Covering Late-Stage

Newly Issued Claims Lengthen Patent Safety to Yr 2039 for Nyxol® Mixture Remedy for Presbyopia

Supplies Broader Safety for Nyxol® Throughout Indications on Strategies of Use as Each day Administration

FARMINGTON HILLS, Mich. , Could 18, 2021 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical firm targeted on creating and commercializing therapies for the remedy of a number of eye problems, introduced right this moment that the US Patent and Trademark Workplace (USPTO) has issued two patents masking the Firm’s late-stage product candidate, Nyxol (phentolamine mesylate). Each patents are directed to classes of material eligible for itemizing within the U.S. FDA Orange Guide:   

  • Nyxol for Remedy of Presbyopia:  U.S. Patent No. 10,993,932 issued on Could 4, 2021 with claims to strategies of treating presbyopia utilizing a mix of phentolamine mesylate and low-dose pilocarpine. The time period of this patent is to yr 2039.
  • Nyxol for Each day Administration:  U.S. Patent No. 11,000,509 issued on Could 11, 2021 with claims to strategies of bettering visible efficiency by each day administration of phentolamine mesylate at or close to bedtime of the affected person alone or together with a number of extra therapeutic brokers. The time period of the patent is to yr 2034.

“We’re fairly happy to announce the issuance of those two new U.S. patents that additional strengthen our already sturdy patent portfolio for Nyxol,” mentioned Mina Sooch, MBA, President and CEO of Ocuphire Pharma. “As we proceed to satisfy milestones in our ongoing scientific trials investigating Nyxol for numerous refractive indications, patents like these present the safety essential to make sure business success. Importantly, Ocuphire owns the entire worldwide rights to Nyxol for all indications. These broader and new claims for each day use and presbyopia respectively mirror a number of years of strategic effort by our group and our patent counsel Dechert LLP. The timing is right with our current announcement of enrollment completion within the VEGA-1 Section 2 presbyopia trial and the upcoming anticipated top-line outcomes by the tip of June.”

Nyxol® Eye Drops Patent Property

Ocuphire’s patent property for Nyxol consists of patents and patent functions for phentolamine mesylate formulations and strategies of utilizing phentolamine mesylate. Patent expiry on issued patents within the U.S. and globally are no less than by way of 2034. As of Could 17, 2021, Ocuphire’s patent property referring to Nyxol comprises seven issued U.S. patents, 5 pending U.S. non-provisional patent functions, one pending U.S. provisional patent utility, in addition to issued patents in Australia, Europe, Japan, and Mexico and pending patent functions in Australia, Canada, Japan, and different overseas nations. Ocuphire owns the entire worldwide rights to Nyxol for all indications.

About Ocuphire Pharma

Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical firm targeted on creating and commercializing therapies for the remedy of a number of eye problems. Ocuphire’s pipeline presently consists of two small-molecule product candidates concentrating on back and front of the attention indications. The corporate’s lead product candidate, Nyxol® (0.75% phentolamine ophthalmic resolution) Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to cut back pupil dimension, and is being developed for a number of indications, together with dim gentle or evening imaginative and prescient disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 8 scientific trials together with the just lately accomplished Section 3 trial in RM. Ocuphire reported constructive topline information in March 2021 for MIRA-2, a Section 3 FDA registration examine for remedy of RM. Nyxol can also be presently in Section 3 scientific improvement for NVD and in Section 2 for presbyopia. Ocuphire’s second product candidate, APX3330, is an oral pill designed to inhibit angiogenesis and irritation pathways related to retinal and choroidal vascular illnesses, akin to diabetic retinopathy (DR) and diabetic macular edema (DME) and has been studied in 11 Section 1 and a pair of trials. APX3330 is presently enrolling topics in a Section 2 scientific trial in topics with DR/DME. As a part of its technique, Ocuphire will proceed to discover alternatives to accumulate extra ophthalmic property and to hunt strategic companions for late-stage improvement, regulatory preparation, and commercialization of medication in key world markets. Please go to www.clinicaltrials.gov to study extra about Ocuphire’s accomplished Section 2 trials, just lately accomplished Section 3 registration trial (NCT04620213), ongoing Section 3 registration trial (NCT04638660), Section 2 trial in presbyopia (NCT04675151), and Section 2 trial in DR/DME (NCT04692688). For extra info, please go to www.ocuphire.com

Ahead Wanting Statements

Statements contained on this press launch relating to issues that aren’t historic information are “forward-looking statements” throughout the that means of the Personal Securities Litigation Reform Act of 1995. Such statements embrace, however should not restricted to, statements regarding Ocuphire’s product candidates, outcomes of ongoing and future scientific trials, and commercialization and market alternatives. These forward-looking statements are primarily based upon Ocuphire’s present expectations and contain assumptions which will by no means materialize or might show to be incorrect. Precise outcomes and the timing of occasions may differ materially from these anticipated in such forward-looking statements because of numerous dangers and uncertainties, together with, with out limitation: (i) the success and timing of regulatory submissions and pre-clinical and scientific trials, together with enrollment and information readouts; (ii) regulatory necessities or developments; (iii) modifications to scientific trial designs and regulatory pathways; (iv) modifications in capital useful resource necessities; (v) dangers associated to the shortcoming of Ocuphire to acquire ample extra capital to proceed to advance its product candidates and its preclinical applications; (vi) legislative, regulatory, political and financial developments, (vii) modifications in market alternatives, (viii) the consequences of COVID-19 on scientific applications and enterprise operations, (ix) the success and timing of commercialization of any of Ocuphire’s product candidates and (x) the upkeep of Ocuphire’s mental property rights. The foregoing overview of vital components that might trigger precise occasions to vary from expectations shouldn’t be construed as exhaustive and needs to be learn along side statements which can be included herein and elsewhere, together with the chance components detailed in paperwork which were and could also be filed by Ocuphire now and again with the SEC. All forward-looking statements contained on this press launch communicate solely as of the date on which they had been made. Ocuphire undertakes no obligation to replace such statements to mirror occasions that happen or circumstances that exist after the date on which they had been made.

Ocuphire Contacts

Mina Sooch, President & CEO  
Ocuphire Pharma, Inc.  

Corey Davis, Ph.D. 
LifeSci Advisors 

Source link

Related posts

Leave a Comment